Casey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.
Casey M. Cosgrove, MD
Advertisement
Articles by Casey M. Cosgrove, MD
Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.
Casey M. Cosgrove, MD, discusses the approval of niraparib in advanced ovarian cancer.
Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center–James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.
Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Cosgrove on Retreatment With PARP Inhibitors in Ovarian CancerDecember 17th 2019
Dr. Cosgrove on the Approval of Niraparib in Advanced Ovarian CancerJanuary 24th 2020
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5